Brought to you by 
Merck pays €110mm up front for rights to AiCuris’s HCMV candidates
07 Dec 2015
Executive Summary
AiCuris GMBH & Co. KG (antiviral and antibacterial drug development) has granted Merck & Co. Inc. exclusive worldwide rights to its pipeline of candidates for the treatment and prevention of human cytomegalovirus (HCMV) infection in bone marrow transplant patients, including lead compound letermovir (AIC246).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com